Alex Gorsky, CEO of Johnson & Johnson (JNJ), will remain on a presidential advisory panel, declining to join an exodus of executives that began with his counterpart at Merck, who stepped down in response to President Trump’s initially tepid criticism of the white nationalists at the center of the violent protests over the weekend in Charlottesville, Va.

“In the end, I have concluded that Johnson & Johnson has a responsibility to remain engaged, not as a way to support any specific political agenda, but as a way to represent the values of Our Credo as crucial public policy is discussed and developed,” Gorsky said in a statement released by J&J on Tuesday afternoon.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The decision to remain on the advisory council is unacceptable and cowardly. The fact that the racist coward in the White House disbanded the council today doesn’t save JNJ. Will be selling my stock in this company and evaluating alternative products so I can purge my home of their products. I am beyond disappointed in JNJ.

    • Hope you sell many shares, I’ll gladly buy on the dip. You must not need that fat dividend either that J&J gives, but I’ betting you won’t send the mony back.

  • Feel nothing but contempt for J and J. The deregulation of medicines fully serves their agenda. Read up on their psych meds. The executives of this once trusted ‘family’ company will rot in hell (if there is one) beside their tobacco industry brothers. The worst.

  • Presidential Advisory Groups are more sizzle than steak, generally unproductive, buff and butt stops (buff the resume, kiss some presidentual butt).

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy